What are the predictors of fracture in #SLE? 🦴Prednisone! Even at low doses ≤5mg 🦴Stroke 🦴Caucasian race 🦴Female 🦴Low BMD Try to avoid steroid use. If they are needed, IM triamcinolone or IVMP preferable to oral GC. Ab2679 #ACR24 @RheumNow

Data from the RISE registry show that 9.3% of SLE pts had thrombocytopenia and a smaller percentage with mod-severe TP (2.7%). Severe TP was much rare. Large data, but well represented grp? @RheumNow #ACR24 abs2680 https://t.co/Y1Lo9lJGtO

• https://x.com/RHEUMarampa/status/1858919555143278976/photo/1
• https://x.com/RHEUMarampa/status/1858919555143278976/photo/1
• https://x.com/RHEUMarampa/status/1858919555143278976/photo/1

Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o

• https://x.com/i/web/status/1858887962349760575

In Vivo CAR T Cell Therapy. A single intralymphatic injection of VivoVec™ particles: - Generates functional CAR T cells in vivo - Achieves complete B cell depletion in NHPs without lymphodepletion - Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V

• https://x.com/i/web/status/1858891733259427881
• https://x.com/synovialjoints/status/1858891733259427881/photo/1

🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1

• https://x.com/bella_mehta/status/1858893243057897860/photo/1

Severe thrombocytopenia (TP) is rare but linked to major organ involvement and poor prognosis in #SLE. Data from the RISE registry shows TP in 9.3% of SLE patients, with higher prevalence in males, African-Americans+ those with multiple comorbidities. #ACR24 @RheumNow abst#2680

In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity. Mechanism? NAC reduces rapamycin (mTOR) activation. Common AEs: nausea, vomiting @RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP

• https://x.com/RHEUMarampa/status/1858907159624339570/photo/1
• https://x.com/RHEUMarampa/status/1858907159624339570/photo/1

PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts 1 MI & 1 death from infection over 213 pts Encouraging for sure! Second phase 3 being launched #ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb

• https://x.com/EBRheum/status/1858865337334211065/photo/1
• https://x.com/EBRheum/status/1858865337334211065/photo/1
• https://x.com/EBRheum/status/1858865337334211065/photo/1
• https://x.com/EBRheum/status/1858865337334211065/photo/1